Teva to create generic drug giant in $7.5bn Barr buyout
Saturday 19 July 2008
The increase in merger deals involving generic drug companies has continued apace after Israel's Teva Pharmaceuticals announced it was buying its American rival Barr, the fourth-biggest group in the sector, for $7.5bn (£3.75bn).
The friendly deal will combine the generalist group Teva with Barr, which specialises in female healthcare, giving the merged company more than 500 products and sales worth $11.9bn. Teva will pay $66.50 for each share, which represents a 32 per cent premium to Barr's average share price over the past two years and 42 per cent above where the stock closed on Wednesday. The acquisition price also includes Barr's debt.
Teva hopes the deal will cement its place as one of the leading off-patent drugs producers in the US, as well as establishing its position in Europe. The combined group has as many as 70 patent challenges in the pipeline. "The combination of our two companies provides an outstanding opportunity strategically and economically: it will enhance our market share and leadership position in the US and key global markets," said Teva's chief executive Shlomo Yanai.
Andreas Theisen, an analyst at WestLB in Germany, said the deal comes as something of a surprise. "We would not have thought that Teva was interested in the US operation where it has undoubtedly been attracted to Barr's very specialised oral contraceptive business. The price looks pretty cheap at a multiple of just 12.7 times Ebitda, most deals in the past three or four years have come at around 15 to 16 times. This certainly leaves the door open for others to bid for Barr." According to Mr Theisen, the agreement includes a $200m break clause, which is payable to Teva if Barr withdraws from the merger.
Generic drugs companies operate by producing treatments that were originally developed by the branded sector, but where patents have lapsed. Increasingly, generics groups are challenging patents in the courts. Earlier this month, Teva was dealt as blow when a New Jersey district judge awarded Astra-Zeneca a summary judgment in a case where Teva had sought to set aside the patent protecting the schizophrenia drug Seroquel. Teva conceded it had breached AstraZeneca's copyright, but claimed the branded group had acted inequitably.
Yesterday's deal is the latest in a line of merger deals involving the generic drugs industry. Last month, Japan's third-biggest pharmaceuticals group, Daiichi Sankyo, bought a 35 per cent share in India's largest generic drugs maker, Ranbaxy, for $4.6bn. One analyst in London said that the latest wave of deals was nothing new. "We have been here before and historically these deals do not work very well," said the analyst. "The only merger that has succeeded in recent times was Novartis' buyout of Sandoz."
- 1 Tourist films plane's descent just metres above packed Caribbean beach
- 3 World Book Day: Boy 'excluded' from school after dressing up as Fifty Shades' Christian Grey
- 4 Bad Jews poster 'censored' on London Tube
- 5 Have sex with your iPad thanks to the new sex toy no-one asked for
Tourist films plane's descent just metres above packed Caribbean beach
Indian woman creates 'Marriage CV' after parents put her on dating site: 'Definitely not marriage material. Won’t grow long hair, ever'
Isis 'bulldozes' Nimrud: UNESCO condemns destruction of ancient Assyrian site as a 'war crime'
Professor Brian Cox brands astrology-believing Tory MP David Tredinnick an 'outlier on the spectrum of reason'
Lynch mob kills suspected rapist in India after dragging him naked for four miles through city
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
Durham Free School: 'Creationism taught at' free school facing closure
End of the licence fee: BBC to back radical overhaul of how it is funded
Elif Shafak: Turkish author warns against rise of British nationalism
Ex-head of MI6: 'We shouldn't kid ourselves that Russia is on a path to democracy'
Most people think legal tax avoidance is just as wrong as illegal tax evasion, poll suggests
iJobs Money & Business
£13000 per annum: Recruitment Genius: This is an exciting opportunity to join ...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
£12 - £15 Hourly Rate: Jemma Gent: In this role you will report to the Head of...
£8 per hour: Recruitment Genius: This Pension Specialist was established early...